Conference Correspondent

Update from the RESONATE Trial: Ibrutinib versus Ofatumumab in Relapsed/Refractory CLL

ASH 2014 - CLL, ASH Highlights

Conference Correspondent — January 13, 2015

The Benefit of Adding Rituximab to Ibrutinib in Relapsed/Refractory CLL

ASH 2014 - CLL, ASH Highlights

Conference Correspondent — January 13, 2015

Interim Analysis of the PROLONG Study: Ofatumumab Maintenance Therapy in Patients with Relapsed CLL

ASH 2014 - CLL, ASH Highlights

Conference Correspondent — January 13, 2015

Ibrutinib Salvage in Relapsed CLL After Allogeneic Transplantation

ASH 2014 - CLL, ASH Highlights

Conference Correspondent — January 13, 2015

Final Results from the CLL20 Study: Alemtuzumab plus Dexamethasone in Very High–Risk Patients with CLL

ASH 2014 - CLL, ASH Highlights

Conference Correspondent — January 13, 2015

Ibrutinib-Based Regimens for Patients with Relapsed/Refractory CLL: Impact of Complex Karyotype

ASH 2014 - CLL, ASH Highlights

Conference Correspondent — January 13, 2015

Frontline Chemoimmunotherapy with Fludarabine/Cyclophosphamide/Rituximab versus Bendamustine/Rituximab in Advanced CLL: Final Analysis of the CLL10 Study

Conference Correspondent — January 13, 2015

Ibrutinib Monotherapy in Patients with Relapsed/Refractory Follicular Lymphoma

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent — January 9, 2015

Safety and Efficacy of Ibrutinib plus Rituximab in Relapsed Mantle-Cell Lymphoma

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent — January 9, 2015

Combination of Ibrutinib and BCL-2 or Spleen Tyrosine Kinase Inhibitors in Ibrutinib-Resistant Diffuse Large B-Cell Lymphoma

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent — January 9, 2015

Page 33 of 44

30
31
32
33
34
35
36